Clinical Trials Browser

Neoplasms × osimertinib × 30 days × Clear all

NCT07005102 2026-05-22

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Neoplasms

NCT05647122 2026-05-11

EGRET

Phase 1 Recruiting

GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms